Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001178913-24-001006 Act: 33 Size: 436 KB 网页链接
$Sol-gel(SLGL)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-000932 Act: 34 Size: 10 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000927 Act: 34 Size: 675 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000832 Act: 34 Size: 28 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000767 Act: 34 Size: 15 KB 网页链接
$Sol-gel(SLGL)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001406 Act: 34 Size: 90 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000472 Act: 34 Size: 92 KB 网页链接
$Sol-gel(SLGL)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000307 Act: 34 Size: 56 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000223 Act: 34 Size: 321 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000189 Act: 34 Size: 134 KB 网页链接